Adjuvant and Neoadjuvant Therapies in High-Risk Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Adjuvant and Neoadjuvant Therapies in High-Risk Renal Cell Carcinoma

Published:2011-08 Issue:4 Volume:25 Page:765-791
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Smaldone Marc C.,Fung Chunkit,Uzzo Robert G.,Haas Naomi B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference130 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Rising incidence of renal cell cancer in the United States;Chow;JAMA,1999

3. Rising incidence of small renal masses: a need to reassess treatment effect;Hollingsworth;J Natl Cancer Inst,2006

4. Increased incidence of serendipitously discovered renal cell carcinoma;Jayson;Urology,1998

5. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort;Frank;J Urol,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction;OncoTargets and Therapy;2023-01

2. Renal cell carcinoma—presentation highlights from the ESMO Congress 2021;memo - Magazine of European Medical Oncology;2022-04-01

3. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management;Current Treatment Options in Oncology;2022-03-22

4. Safety of Immune Checkpoint Inhibitors in the Peri-operative Setting;Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers;2022

5. Urologic Cancer Molecular Biology;Biomedical Engineering;2021-12-03